SAN DIEGO & EWING, N.J.--(BUSINESS WIRE)--Aug 7, 2018--Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. (NasdaqCM: ATRS) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 21, 2016 and October 12, 2017. Antares, a specialty pharmaceutical company, develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. Antares' lead product candidate is known as Xyosted.

View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/antares-pharma-inc-aug-2018/

Antares Accused of Overstating Approval Prospects for its Drug

According to the complaint, on December 21, 2016, Antares announced its submission of a New Drug Application ("NDA") for Xyosted to the U.S. Food and Drug Administration ("FDA") and spoke optimistically about the drug's potential. However, Antares officials provided insufficient data to the FDA for the NDA and overstated the approval prospects for Xyosted. On October 12, 2017, Antares revealed that FDA had "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for Xyosted. On this news, Antares' stock fell nearly 38% to close at $2.32 per share on October 13, 2017. On October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA stating that the FDA cannot approve the NDA due to concerns about increase in blood pressure and the occurrence of depression and suicidality.

Antares Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Sign up for our FREE portfolio monitoring service, Stock Watch.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180807005888/en/

CONTACT: Robbins Arroyo LLP

Leonid Kandinov

(619) 525-3990 or Toll Free (800) 350-6003

LKandinov@robbinsarroyo.com

www.robbinsarroyo.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW JERSEY

INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL

SOURCE: Robbins Arroyo LLP

Copyright Business Wire 2018.

PUB: 08/07/2018 04:00 PM/DISC: 08/07/2018 04:01 PM

http://www.businesswire.com/news/home/20180807005888/en